Should Moderna prioritize expanding manufacturing capacity for existing vaccines or investing in research for new mRNA therapies?

Introduction

The trade-off question at hand is whether Moderna should prioritize expanding manufacturing capacity for existing vaccines or investing in research for new mRNA therapies. This scenario involves balancing short-term production capabilities with long-term innovation potential. I'll analyze this trade-off by examining the business context, stakeholder impacts, and potential outcomes to provide a strategic recommendation.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking Moderna's current vaccine portfolio is primarily focused on COVID-19. Could you provide an overview of Moderna's existing vaccine lineup and their market performance?

Why it matters: Helps assess the stability and growth potential of current products Expected answer: Strong COVID-19 vaccine sales, with potential for other vaccines in development Impact on approach: Would influence the urgency of expanding manufacturing vs. diversifying

• Business Context: Based on industry trends, I assume mRNA technology has applications beyond vaccines. What are Moderna's strategic priorities for the next 3-5 years in terms of product diversification?

Why it matters: Aligns decision with long-term company vision Expected answer: Balanced approach, with focus on both vaccine production and new therapeutic areas Impact on approach: Would help determine the optimal resource allocation between manufacturing and R&D

• User Impact: Considering global health needs, which patient populations or disease areas are we targeting with potential new mRNA therapies?

Why it matters: Identifies key stakeholders and potential market size for new therapies Expected answer: Focus on high-impact areas like oncology, rare diseases, or emerging infectious diseases Impact on approach: Would influence the urgency and potential ROI of investing in new therapies

• Technical: What's our current manufacturing capacity utilization, and how scalable is our existing infrastructure for potential new therapies?

Why it matters: Assesses the need and feasibility of expanding manufacturing Expected answer: High utilization for COVID vaccines, with some flexibility for new products Impact on approach: Would determine the urgency and cost-effectiveness of expanding manufacturing

• Resource: Can you share insights on our current R&D pipeline and team capacity for developing new mRNA therapies?

Why it matters: Evaluates internal capabilities and resource constraints Expected answer: Strong but stretched R&D team, with several promising candidates in early stages Impact on approach: Would influence the timeline and resource allocation for new therapy development